Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 3 | 2022 | 371 | 0.770 |
Why?
|
| Lung Neoplasms | 6 | 2025 | 1493 | 0.730 |
Why?
|
| Biomimetics | 1 | 2021 | 18 | 0.700 |
Why?
|
| Cisplatin | 1 | 2021 | 269 | 0.630 |
Why?
|
| Lung Transplantation | 1 | 2022 | 344 | 0.550 |
Why?
|
| Mesothelioma | 3 | 2024 | 90 | 0.550 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 579 | 0.550 |
Why?
|
| Peptide Fragments | 1 | 2021 | 756 | 0.530 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2016 | 70 | 0.480 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2016 | 103 | 0.440 |
Why?
|
| Neoplasm Staging | 5 | 2025 | 1284 | 0.430 |
Why?
|
| Metastasectomy | 1 | 2013 | 11 | 0.420 |
Why?
|
| Pneumonectomy | 2 | 2026 | 149 | 0.420 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 973 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1931 | 0.410 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1560 | 0.400 |
Why?
|
| Pleural Neoplasms | 2 | 2024 | 72 | 0.390 |
Why?
|
| Second-Look Surgery | 1 | 2010 | 4 | 0.330 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2010 | 13 | 0.330 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 53 | 0.320 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 53 | 0.310 |
Why?
|
| Laparotomy | 1 | 2010 | 144 | 0.300 |
Why?
|
| Breast Implants | 1 | 2026 | 30 | 0.240 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 622 | 0.210 |
Why?
|
| Watchful Waiting | 1 | 2024 | 73 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1302 | 0.200 |
Why?
|
| Thoracic Surgery | 1 | 2025 | 159 | 0.200 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 17 | 0.180 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 66 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 316 | 0.170 |
Why?
|
| Drug Synergism | 1 | 2021 | 232 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 169 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2025 | 741 | 0.170 |
Why?
|
| Melanoma | 2 | 2022 | 898 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2026 | 12546 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 985 | 0.160 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 38 | 0.130 |
Why?
|
| Humans | 14 | 2026 | 126753 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 880 | 0.110 |
Why?
|
| Apoptosis | 1 | 2021 | 1811 | 0.110 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2397 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2026 | 3066 | 0.100 |
Why?
|
| Disease Management | 1 | 2016 | 541 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2024 | 6214 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1758 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1559 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 33 | 0.080 |
Why?
|
| Leucovorin | 1 | 2010 | 52 | 0.080 |
Why?
|
| Sample Size | 1 | 2010 | 83 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2010 | 132 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 377 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 898 | 0.070 |
Why?
|
| Time Factors | 2 | 2024 | 6134 | 0.070 |
Why?
|
| Biomarkers | 1 | 2016 | 3222 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 398 | 0.060 |
Why?
|
| Tissue Expansion Devices | 1 | 2026 | 10 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2009 | 458 | 0.060 |
Why?
|
| Female | 6 | 2026 | 68330 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2009 | 683 | 0.050 |
Why?
|
| Male | 5 | 2024 | 62543 | 0.050 |
Why?
|
| Syndrome | 1 | 2026 | 1137 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17005 | 0.050 |
Why?
|
| Mutation | 1 | 2016 | 5941 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 4954 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 63 | 0.050 |
Why?
|
| Aged | 3 | 2024 | 20344 | 0.040 |
Why?
|
| Infant | 1 | 2016 | 12771 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 284 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2010 | 3586 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2016 | 14347 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 379 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 352 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 478 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1193 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1536 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1220 | 0.030 |
Why?
|
| Survival Rate | 1 | 2022 | 2101 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2039 | 0.030 |
Why?
|
| Middle Aged | 3 | 2024 | 27697 | 0.030 |
Why?
|
| Child | 1 | 2016 | 25101 | 0.030 |
Why?
|
| Risk Factors | 1 | 2010 | 10555 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 4772 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1259 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 6668 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 2029 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 3262 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9665 | 0.020 |
Why?
|
| Melanocytes | 1 | 2009 | 44 | 0.020 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2009 | 55 | 0.020 |
Why?
|
| Uveitis | 1 | 2009 | 30 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 1 | 2009 | 57 | 0.020 |
Why?
|
| Autoantigens | 1 | 2009 | 104 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2009 | 265 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 283 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 228 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 30410 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2009 | 354 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2009 | 199 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 20002 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2009 | 890 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 2310 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 17596 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 33051 | 0.000 |
Why?
|